Moderna on Friday said the Food and Drug Administration has postponed an approval decision on its experimental vaccine for ... t expect major delays from here onwards and FDA should be able ...
Moderna will have to consider that after receiving word that the FDA will not meet a May 12 decision date for its respiratory syncytial virus (RSV) vaccine candidate. The vaccine maker said Friday ...
US regulators’ decision on whether to approve Moderna Inc.’s vaccine for RSV has been delayed due to ... get its second product to market. The FDA hasn’t informed Moderna of any issues ...
The Food and Drug Administration (FDA) has informed Moderna that its review of the Biologics License Application (BLA) for mRNA-1345, an investigational respiratory syncytial virus (RSV ...
its investigational respiratory syncytial virus or RSV vaccine, will be delayed. In pre-market activity on the Nasdaq, Moderna shares were losing around 2.3 percent to trade at $119.91. The FDA ...
Moderna (NASDAQ:MRNA) shares are down just over 1% in early Friday trading after the company said the FDA ... RSV vaccine due to "administrative constraints." However, they remain on track for a ...
London: The U.S. drug regulator has pushed back its decision ... vaccine, its only marketed product, after the pandemic. Moderna was seeking the FDA's approval for using the shot to prevent RSV ...